Lack of neutralizing activity in nonconvalescent sera, regardless of ABO blood group and anti-A isoagglutinin titer.
ABO blood group
Anti-A isoagglutinins
COVID-19
Convalescent plasma
Neutralizing antibody
SARS-CoV-2
Journal
Journal of clinical virology plus
ISSN: 2667-0380
Titre abrégé: J Clin Virol Plus
Pays: England
ID NLM: 9918283581506676
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
27
05
2021
revised:
30
07
2021
accepted:
06
08
2021
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
ppublish
Résumé
Several ABO blood groups have been associated with the likelihood of infection, severity, and/or outcome of COVID-19 in hospitalized cohorts, raising the hypothesis that anti-A isoagglutinins in non-A-group recipients could act as neutralizing antibodies against SARS-CoV-2. We run live virus neutralization tests using sera from 58 SARS-CoV-2 seronegative blood donors (27 O-group and 31 A-group) negatives for SARS-CoV-2 IgG to investigate what degree of neutralizing activity could be detected in their sera and eventual correlation with anti-A isoagglutinin titers. We could not find clinically relevant neutralizing activity in any blood group, regardless of anti-isoagglutinin titer. Our findings suggest that mechanisms other than neutralization explain the differences in outcomes from COVID19 seen in different ABO blood groups.
Sections du résumé
Background
UNASSIGNED
Several ABO blood groups have been associated with the likelihood of infection, severity, and/or outcome of COVID-19 in hospitalized cohorts, raising the hypothesis that anti-A isoagglutinins in non-A-group recipients could act as neutralizing antibodies against SARS-CoV-2.
Materials and methods
UNASSIGNED
We run live virus neutralization tests using sera from 58 SARS-CoV-2 seronegative blood donors (27 O-group and 31 A-group) negatives for SARS-CoV-2 IgG to investigate what degree of neutralizing activity could be detected in their sera and eventual correlation with anti-A isoagglutinin titers.
Results
UNASSIGNED
We could not find clinically relevant neutralizing activity in any blood group, regardless of anti-isoagglutinin titer.
Discussion
UNASSIGNED
Our findings suggest that mechanisms other than neutralization explain the differences in outcomes from COVID19 seen in different ABO blood groups.
Identifiants
pubmed: 35262018
doi: 10.1016/j.jcvp.2021.100035
pii: S2667-0380(21)00027-2
pmc: PMC8349435
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100035Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
We declare we have no conflict of interest related to this manuscript.
Références
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Clin Infect Dis. 2021 Jun 1;72(11):e919
pubmed: 32997752
Vox Sang. 2021 Feb;116(2):251-252
pubmed: 33103769
Clin Microbiol Rev. 2020 Aug 12;33(4):
pubmed: 32792417
Blood Coagul Fibrinolysis. 2021 Jan 1;32(1):44-49
pubmed: 33417336
Int J Infect Dis. 2021 Mar;104:242-249
pubmed: 33326874
Thromb J. 2007 Sep 25;5:14
pubmed: 17894864
Life (Basel). 2021 Apr 01;11(4):
pubmed: 33915711
Int J Clin Pract. 2021 Apr;75(4):e13927
pubmed: 33296536
Blood Rev. 2021 Jul;48:100785
pubmed: 33309392
Vox Sang. 2021 Apr;116(4):471-472
pubmed: 33326616
Haematologica. 2020 Jul 23;105(12):2841-2843
pubmed: 33256383
Br J Haematol. 2020 Aug;190(3):e148-e150
pubmed: 32516462
Thromb Res. 2021 Jan;197:172-178
pubmed: 33221577
Sci Rep. 2019 Sep 19;9(1):13535
pubmed: 31537816
Liver Int. 2020 Jun;40(6):1415-1426
pubmed: 32052552
BMC Med. 2020 Nov 17;18(1):334
pubmed: 33198801
Med Clin (Engl Ed). 2020 Oct 23;155(8):340-343
pubmed: 33015369
Glycobiology. 2008 Dec;18(12):1085-93
pubmed: 18818423